UCSF researcher Christine Miaskowski, RN, PhD and colleagues are conducting a research study to learn more about the signs and symptoms of lymphedema associated with breast cancer treatments. Lymphedema is the swelling in the arms, shoulders, hands and/or breast area as a result of breast cancer treatment. The team also wants to know if there are genetic, (i.e., inherited) factors that predict whether patients develop lymphedema or not.
To be eligible to participate in the Risk Factors of Breast Cancer Lymphedema Study, you must:
• Be female, at least 18 years old
• Have had breast cancer on one side only
• Completed surgery for breast cancer & any other breast cancer treatment (radiation and chemotherapy) at least 6 months ago
• Have a diagnosis of breast cancer treatment-related lymphedema
Participants will complete online questionnaires and have a one-time study visit to UCSF, Parnassus campus. Participants will be paid $150 for their time and travel.
To find out if you qualify or for other questions, contact the study research team at 855-855-UCSF (855-855-8273) toll free or email Judy Mastick, RN, study project director, at firstname.lastname@example.org.
Vanderbilt University School of Nursing in Nashville, TN is conducting a study to test an online survey for people with some type of chronic swelling (lymphedema), including head and neck, back, chest, breast, abdomen/belly, groin, and genital swelling.
Participation is confidential and involves a one minute online screening survey and, if eligible, a one-time half-hour or less online survey.
You would not be paid to be in the study, but in just a few minutes you can help us to know more about the problems people with these types of chronic swelling (lymphedema) have.
Learn More >
Vanderbilt University School of Nursing in Nashville, TN is conducting a study to test an online survey for people with NO lymphedema and people with leg (lower limb) lymphedema.
Participation involves a quick online screening survey and, if eligible, a one-time twenty minute or less online survey.
There is no compensation for this study, but in just a few minutes you can help us better understand the problems people with this type of lymphedema experience.
This study is now closed.Learn More >
Clinical Trial at Stanford School of Medicine:
Dr. Joyce Teng, MD, PhD at Stanford University School of Medicine, CA is conducting a clinical trial on the use of Sildenafil treatment for patients ages 6 months - 10 years of age with Lymphatic Malformations (LM).
Participation involves visits to Stanford, as well as at local sub-sites being conducted in Chicago, IL, and Denver, Colorado. Duration is 20 - 52 weeks. There is no compensation for this study, but all travel is covered by Stanford. A separate study is also being conducted, which involves genetic testing of patients with lymphatic malformations.
To find out more information or to see if your child qualifies, please contact Elidia Tafoya, MPH, study coordinator, at 650-724-1982 or by email at email@example.com. To view clinical study flyer, click here.Learn More >
For women and men who have lymphedema of the arm, there is a growing interest in lymph node transfer as a surgical solution. Dr. Stanley G. Rockson and his research team at Stanford University are currently studying lymph node transfer for arm lymphedema, to determine the best possible approaches for a favorable outcome to the surgery. If you have arm lymphedema and are contemplating lymph node transfer surgery, you may be eligible to participate in this study. For more information, please call Eric Henderson at 650-723-1396 or e-mail firstname.lastname@example.org.
For general information about participant rights, contact: 1-866-680-2906.
Parents of children who have been diagnosed with lymphedema are invited to participate in a research study at Miami University (Ohio). The purpose of this study is to better understand the experiences of biological parents of children with lymphedema.
They are interested in learning more from you about what it is like for you in caring for a child with primary lymphedema. Specifically, they want to know about your unique challenges as a parent, your role as an advocate for their child in health care, school-based, and other settings, how you explain lymphedema to your children and how you help your children in turn explain lymphedema to others.
Volunteers will participate in an informal interview over the telephone, via video conference (e.g, FaceTime, Skype, Google Hangout), or face-to-face with an interviewer. The interview may last up to one hour
This study has been approved by the Miami University Institutional Review Board: 01182r.
If you would like to participate in this opportunity, please contact the Principal Investigator:
Elise Radina, PhD, CFLE
Professor and Acting Chair
Family Studies & Social Work
For more information and/or scheduling a study appointment, please contact Pamela Ostby, PhD(c), RN, OCN® at 314/255-6677 or you can email email@example.com.
Learn More >
ULTRA is Ubenimex in adult patients with secondary Lymphedema of the lower limb: a Phase 2, Randomized, double-blind, placebo-controlled study of efficacy, safety, and pharmacokinetics.
Eligible patients must have a diagnosis of secondary leg lymphedema and must have completed a full course of complete decongestive therapy (CDT), at least 8 weeks prior to screening, including use of compression garments for at least 8 weeks without change in regimen. Patients must also be willing to maintain a stable regimen of self-care, including use of compression garments from screening through the entire study duration (through the safety follow-up visit).
Approximately 40 patients will be enrolled in the ULTRA study and will be randomized in a 1:1 ratio to receive ubenimex three times a day or TID (20 patients) or placebo three times a day or TID (20 patients) for 24 weeks.
Inquiries to participate at Stanford University, please contact: Eric Henderson (firstname.lastname@example.org or 650-723-1396). Inquiries to participate at University of Florida Health Cancer Center at Orlando Health, please contact: Teal Stocker (email@example.com or 321-843-2546).Learn More >